Dublin-based biotech Aerska has publicly emerged from stealth mode following a $21 million financing round aimed at advancing its platform for RNA interference (RNAi) therapeutics targeting neurological diseases. By pursuing antibody-oligonucleotide conjugates (AOCs) to deliver RNAi across the blood-brain barrier, Aerska aims to tackle currently underserved neurodegenerative conditions such as genetic forms of Alzheimer's and Parkinson's diseases. The company emphasizes a modular development strategy to accelerate pipeline growth while meeting the high capital needs typical of central nervous system drug development.